Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain P Fraser

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2023
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT SettingThomas Pfeiffer, Ifigeneia Tzannou, Mengfen Wu, et al.
Pediatric Diabetes|October 23, 2018
A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetesIain P Fraser, Naomi D Neufeld, Larry A Fox, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 12, 2018
Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid ModulatorsJason R Clapper, Cassandra L Henry, Micah J Niphakis, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2023
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT SettingThomas Pfeiffer, Ifigeneia Tzannou, Mengfen Wu, et al.
Pediatric Diabetes|October 23, 2018
A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetesIain P Fraser, Naomi D Neufeld, Larry A Fox, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 12, 2018
Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid ModulatorsJason R Clapper, Cassandra L Henry, Micah J Niphakis, et al.
Pageof 2